(secondQuint)A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer.

 This phase II trial will evaluate the combination of fruquintinib and gefitinib in advanced NSCLC.

 The endpoint will be to evaluate the efficacy and safety of the combination.

.

 A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer@highlight

Fruquintinib in combination with Gefitinib as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harboring activating EGFR mutations : a single-arm, multicenter, phase II study